The recent discovery of theNogo family ofmyelin inhibitors and theNogo-66 receptor opens upa very promising avenue for the development of therapeutic agents for treating spinal cord injury. Nogo-A, the largest member of the Nogo fam-ily, is a multidomain protein containing at least two regions responsible for inhibiting central nervous system (CNS) regeneration. So far, no structural information is available for Nogo-A or any of its structural domains. We have sub-cloned and expressed two Nogo-A fragments, namely the 182 residueNogo-A(567–748) and the 66 residueNogo-66 in Escherichia coli
